Selective Serotonin Reuptake Inhibitor Toxicity Medication
- Author: Tracy A Cushing, MD, MPH, FACEP, FAWM; Chief Editor: Asim Tarabar, MD more...
Medication Summary
Pharmacologic treatment of serotonin syndrome (SS) is largely based on anecdotal case reports and on animal models. Supportive care remains the basis of treatment; however, severe cases may benefit from the following interventions:
- Adsorbent antidotes - Activated charcoal
- Serotonin antagonists - Cyproheptadine
- Sedatives and anticonvulsants - Lorazepam, diazepam
- Antihypertensives - Nitroprusside
- Paralytic neuromuscular blockade - Rocuronium, vecuronium
Antidotes, Other
Class Summary
These agents inhibit gastrointestinal absorption of certain toxic agents or irritants. Cyproheptadine and chlorpromazine have been reported to be useful in serotonin syndrome (SS) through blockage of postsynaptic serotonin receptors. No formalized dosing regimens have been established; the following recommendations are based on case reports and reviews of serotonin toxicity treatment.
Activated charcoal (Actidose-Aqua, Actidose with Sorbitol, EZ-Char, Requa Activated Charcoal)
Activated charcoal is used as an emergency treatment for poisoning caused by drugs and chemicals, preventing absorption of a drug by adsorbing the drug in the intestine. The network of pores present in activated charcoal absorbs 100-1000 mg of drug per gram of charcoal. Multidose charcoal may interrupt enterohepatic recirculation and enhance elimination by enterocapillary exsorption.
Theoretically, by constantly bathing the gastrointestinal tract with charcoal, the intestinal lumen serves as a dialysis membrane for reverse absorption of drug from intestinal villous capillary blood into the intestine. Activated charcoal does not dissolve in water.
For maximum effect, administer charcoal within 30-60 minutes after poison ingestion. The addition of sorbitol results in hyperosmotic laxative action, which causes catharsis, further inhibiting intestinal absorption of toxic substances.
Cyproheptadine
Cyproheptadine is an H1-receptor antagonist in blood vessels, the gastrointestinal tract, and the respiratory tract. It has been shown in animal studies and case reports to reduce symptoms of SS. It may be helpful in mild to moderate cases of SS.
Chlorpromazine
Following charcoal administration, chlorpromazine is a better choice in treating toxicity because it can be administered intravenously while cyproheptadine is not available in an intravenous form. However, it is best to avoid chlorpromazine if the drugs inducing serotonin toxicity have significant cardiogenic or epileptogenic properties.
Anxiolytics, Benzodiazepines
Class Summary
Benzodiazepines are considered a mainstay of serotonin syndrome (SS) treatment, particularly as a therapy for neuromuscular symptoms and seizures. They are also excellent for controlling agitated behavior.
Lorazepam (Ativan)
Lorazepam is a sedative with rapid onset and a relatively long half-life. By increasing the action of gamma-aminobutyric acid (GABA), which is a major inhibitory neurotransmitter in the brain, it may depress all levels of the central nervous system (CNS), including the limbic and reticular formation. Lorazepam's anticonvulsant effects last longer than those of diazepam or midazolam (4-6 h).
Diazepam (Valium, Diastat)
Diazepam modulates postsynaptic effects of GABA-A transmission, resulting in an increase in presynaptic inhibition. It appears to act on part of the limbic system, thalamus, and hypothalamus to induce a calming effect. Diazepam has also been found to be an effective adjunct for the relief of skeletal muscle spasm caused by upper motor neuron disorders.
Diazepam rapidly distributes to other body fat stores. Twenty minutes after the drug's initial IV infusion, diazepam's serum concentration drops to 20% of maximum concentration. Individualize the dosage and increase it cautiously to avoid adverse effects.
Clonazepam (Klonopin)
Clonazepam is an anticonvulsant that may be useful in the setting of myoclonus.
Vasodilators
Class Summary
Antihypertensives are used for the treatment of autonomic instability and malignant hypertension as evidenced by end-organ damage to the brain, heart, and/or kidneys.
Nitroprusside (Nitropress)
Nitroprusside produces arterial and venous vasodilation. It decreases afterload and preload and may produce a reflex tachycardia.
Neuromuscular Blockers, Depolarizing
Class Summary
To control hyperreflexia, clonus, and hyperthermia, total neuromuscular paralysis may be required. Succinylcholine should be avoided in serotonin syndrome (SS), given the risk of hyperkalemia secondary to rhabdomyolysis.
Rocuronium (Zemuron)
Rocuronium is a nondepolarizing neuromuscular blocking agent with rapid to intermediate onset (depending on dose) and intermediate duration. It competes for cholinergic receptors at the motor end-plate to antagonize the action of acetylcholine, which in turn blocks neuromuscular transmission. Acetylcholinesterase inhibitors such as neostigmine and edrophonium antagonize action.
Vecuronium
Vecuronium is a prototypic, nondepolarizing neuromuscular blocking agent that reliably results in muscular paralysis. For intubation and maintenance of paralysis, a continuous infusion may be used.
Infants are more sensitive to neuromuscular blockade activity and, although the same dose is used, recovery is prolonged by 50%. Vecuronium is not recommended for use in neonates.
Sternbach H. The serotonin syndrome. Am J Psychiatry. Jun 1991;148(6):705-13. [Medline].
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. Mar 17 2005;352(11):1112-20. [Medline].
Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. Jan 9 2002;287(2):203-9. [Medline].
Pirraglia PA, Stafford RS, Singer DE. Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. Prim Care Companion J Clin Psychiatry. Aug 2003;5(4):153-157. [Medline].
Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. Jun 1 2006;42(11):1578-83. [Medline].
Kaplan H, Sadock B. Serotonin-specific reuptake inhibitors. In: Synopsis of Psychiatry. 8th ed. Williams and Wilkins; 1988:1083-92.
Hirsch M, Birnbaum R. Pharmacology of Antidepressants. UpToDate [serial online]. 2004;v 11.3..
Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. Jun 1997;17(3):208-21. [Medline].
Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol. Jan 2008;23 Suppl 1:43-51. [Medline].
Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100-9. [Medline].
Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. May 27 2003;168(11):1439-42. [Medline].
Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med. Mar 2003;4(1):63-74. [Medline].
Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). Jul 2000;79(4):201-9. [Medline].
Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-85. [Medline].
US Food and Drug Administration. Celexa (citalopram hydrobromide): Drug Safety Communication – Abnormal Heart Rhythms Associated With High Doses. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm269481.htm. Accessed August 24, 2011.
Celexa (citalopram hydrobromide) [package insert]. St. Louis, Missouri: Forest Pharmaceuticals, Inc; August, 2011. [Full Text].
Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. Jun 2009;104(6):1475-82. [Medline].
Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila). Dec 2010;48(10):979-1178. [Medline].
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. Sep 2003;96(9):635-42. [Medline].
Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit Care Med. Feb 2002;30(2):473-6. [Medline].
[Guideline] Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). May 2007;45(4):315-32. [Medline].
Evans CE, Sebastian J. Serotonin syndrome. Emerg Med J. Apr 2007;24(4):e20. [Medline].
Marx J, Hockberger R, Walls R. Rosen's Emergency Medicine. 5th ed. CV Mosby; 2002:2087-2103.
Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. May 2000;18(2):317-25, x. [Medline].
Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. Sep 17 2007;187(6):361-5. [Medline].
Mills KC. Serotonin syndrome. Am Fam Physician. Oct 1995;52(5):1475-82. [Medline].

